D.A. Davidson & CO. Reduces Position in Gilead Sciences, Inc. (NASDAQ:GILD)

D.A. Davidson & CO. cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 82,224 shares of the biopharmaceutical company’s stock after selling 293 shares during the period. D.A. Davidson & CO.’s holdings in Gilead Sciences were worth $7,595,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of GILD. nVerses Capital LLC purchased a new stake in shares of Gilead Sciences during the third quarter valued at $25,000. HHM Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares during the last quarter. Valued Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares during the last quarter. YANKCOM Partnership purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at $28,000. Finally, Decker Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at $29,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

GILD has been the topic of several research reports. Piper Sandler raised their target price on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Robert W. Baird raised their target price on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Truist Financial raised their target price on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research report on Friday, November 8th. Finally, Morgan Stanley raised their target price on Gilead Sciences from $113.00 to $123.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $102.08.

Gilead Sciences Stock Up 1.1 %

Shares of GILD opened at $105.25 on Wednesday. The business’s 50 day moving average is $94.14 and its 200 day moving average is $87.89. The company has a market capitalization of $131.17 billion, a PE ratio of 1,169.44, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $106.69. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Research analysts expect that Gilead Sciences, Inc. will post 4.35 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 3.00%. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio (DPR) is currently 3,422.22%.

Insider Buying and Selling at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 137,676 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $102.22, for a total value of $14,073,240.72. Following the completion of the transaction, the chief financial officer now owns 171,223 shares of the company’s stock, valued at approximately $17,502,415.06. This trade represents a 44.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 710,500 shares of company stock worth $67,684,956 in the last quarter. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.